Kesios Therapeutics Ltd, a London, UK-based early-stage company developing novel therapeutics for the treatment of multiple myeloma and other cancers, closed a £19m (approx. $28.5m) Series A financing.
Backers included Imperial Innovations Group plc (AIM:IVO), SV Life Sciences and Abingworth. In conjunction with the funding, Kate Bingham, SV Life Sciences, and Kurt von Emster, Abingworth, have joined Kesios’ Board.
Created to commercialize research led by Professor Guido Franzoso from the Department of Medicine at Imperial College London and led by newly appointed Chief Executive Officer Paolo Paoletti, MD, and Chief Scientific Officer Peter Charlton, Kesios is developing drug candidates that exploit a novel target within the nuclear factor kappa B (NF-κB) pathway to promote cancer cell survival in certain white blood cells of patients with multiple myeloma and other malignancies.
KES-0001, the company’s lead drug candidate, is about to enter clinical studies as a potential treatment for multiple myeloma.